TETakayuki Enomoto

Takayuki Enomoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takayuki Enomoto has a total of 155 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Lymphovascular space invasion and risk of lymph Node metastasis in epithelial ovarian cancer

    by K. Matsuo, T. Sheridan, T. Miyake, K. Yoshino, K. Hew, T. Enomoto, D. Im, N. Rosenshein, A. Sood, L. Roman

  • Top Cited Papers
    Open Access

    Therapeutic strategies in epithelial ovarian cancer

    by Ayako Kim, Yutaka Ueda, Tetsuji Naka, Takayuki Enomoto

    Ovarian cancer is the most lethal gynecologic malignancy. It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube. Treatment of epithelial ovarian cancer is based on the combination of cytoreductive surgery and combination chemotherapy using taxane and platinum. Although clear cell type is categorized in indolent type, it is known to show relatively strong resistance to carboplatin and paclitaxel regimen and thus poor prognosis compared to serous adenocarcinoma, especially in advanced stages. Irinotecan plus cisplatin therapy may effective for the clear cell adenocarcinoma. The larger expectation for improved prognosis in ovarian carcinoma is related to the use of the new biological agents. One of the most investigated and promising molecular targeted drugs in ovarian cancer is bevacizumab, a monoclonal antibody directed against VEGF. PARP inhibitor is another one. A few recent studies demonstrated positive results of bevacizumab on progression-free survival in ovarian cancer patients, however, investigation of molecular targeting drugs in patients with ovarian cancer are still underway.


  • Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy

    by Tomomi Egawa-Takata, Yutaka Ueda, Chie Kuragaki, Takahito Miyake, Takashi Miyatake, Masami Fujita, Kiyoshi Yoshino, Ryuichi Nakashima, Mika Okazawa, Tateki Tsutsui, et al.

    TAP chemotherapy (paclitaxel, doxorubicin, and cisplatin) is effective for advanced and recurrent endometrial carcinoma, but has occasional severe toxicity. TEC chemotherapy (paclitaxel, epirubicin, and carboplatin) has been suggested to have less toxicity; however, the optimal dosage has yet to be determined.


  • Usefulness of computed tomography in predicting cytoreductive surgical outcomes for ovarian cancer

    by Kazuko Fujwara, Kiyoshi Yoshino, Takayuki Enomoto, Masami Fujita, Yutaka Ueda, Takashi Miyatake, Toshihiro Kimura, Miho Muraji, Haruyasu Fujita, Tadashi Kimura, et al.

    The objective of this study was to identify features of preoperative computed tomography (CT) scans that can best predict outcomes of primary cytoreductive surgery in ovarian cancer patients.


  • Open Access

    Two Distinct Pathways to Development of Squamous Cell Carcinoma of the Vulva

    by Yutaka Ueda, Takayuki Enomoto, Toshihiro Kimura, Kiyoshi Yoshino, Masami Fujita, Tadashi Kimura

    Squamous cell carcinoma (SCC) accounts for approximately 95% of the malignant tumors of the vaginal vulva and is mostly found in elderly women. The future numbers of patients with vulvar SCC is expected to rise, mainly because of the proportional increase in the average age of the general population. Two different pathways for vulvar SCC have been put forth. The first pathway is triggered by infection with a high-risk-type Human Papillomavirus (HPV). Integration of the HPV DNA into the host genome leads to the development of a typical vulvar intraepithelial neoplasia (VIN), accompanied with overexpression of and . This lesion subsequently forms a warty- or basaloid-type SCC. The HPV vaccine is a promising new tool for prevention of this HPV related SCC of the vulva. The second pathway is HPV-independent. Keratinizing SCC develops within a background of lichen sclerosus (LS) through a differentiated VIN. It has a different set of genetic alterations than those in the first pathway, including p53 mutations, allelic imbalances (AI), and microsatellite instability (MSI). Further clinical and basic research is still required to understand and prevent vulvar SCC.Capsule. Two pathway for pathogenesis of squamous cell carcinoma of the value are reviewed.


  • Open Access

    Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin

    by Yutaka Ueda, Takahito Miyake, Tomomi Egawa-Takata, Takashi Miyatake, Shinya Matsuzaki, Takuhei Yokoyama, Kiyoshi Yoshino, Masami Fujita, Takayuki Enomoto, Tadashi Kimura

    Purpose A combined chemotherapy of taxane and platinum, with or without anthracycline, has been used as a standard first-line regimen. The purpose of this study was to investigate the effectiveness of second-line chemotherapy for treatment of advanced or recurrent endometrial carcinoma previously treated with a combined chemotherapy of taxane and platinum, with or without anthracycline. Methods During the 2000–2008 study period, 723 patients were diagnosed with endometrial cancer at the Departments of Obstetrics and Gynecology of the Osaka University and the Osaka Rosai Hospitals, Osaka, Japan. The subset of these cases that eventually required treatment by second-line chemotherapy was retrospectively analyzed. Results Response rate to second-line chemotherapy was 25%. Treatment-free interval (TFI) of ≥ or P = 0.0026), progression-free survival (P = 0.0003) and overall survival (P = 0.025). The second-line chemotherapy similar to the first-line regimen was ineffective in all the 7 cases (100%) whose TFI was shorter than 6 months. Multivariate analysis showed that TFI was the most significantly important factor predicting the effectiveness of second-line chemotherapy (the adjusted hazard ratio of TFI on PFS and OS: 3.482, 95% CI, 1.641–7.388, P = 0.0012, and 2.341, 95% CI, 1.034–5.301, P = 0.042, respectively). Conclusions Our present study provides, for the first time, evidence that the majority of refractory or recurrent diseases, if they occur within 6 months of a first-line chemotherapy using taxane and platinum with or without anthracycline, are non-responsive to the current regimens of second-line chemotherapy.


  • Open Access

    Serum Biomarkers for Early Detection of Gynecologic Cancers

    by Yutaka Ueda, Takayuki Enomoto, Toshihiro Kimura, Takashi Miyatake, Kiyoshi Yoshino, Masami Fujita, Tadashi Kimura

    Ovarian, endometrial, and cervical cancers are three of the most common malignancies of the female reproductive organs. CA 125, historically the most reliable serum marker for ovarian cancer, is elevated in 50% of early-stage ovarian tumors. For endometrial cancers, there are no established serum markers. SCC, which is the best studied serum marker for squamous cell carcinomas, has been unreliable; SCC is elevated in cervical squamous cell carcinomas ranging from 28–85% of the time. Recent proteomics-based analyses show great promise for the discovery of new and more useful biomarkers. In this review, we will discuss the currently utilized serum tumor markers for gynecologic cancers and the novel biomarkers that are now under investigation.


  • Clinical trials of WT1 peptide vaccine to gynecologic malignancies that are resistant to conventional therapies.

    by T. Miyatake, T. Enomoto, Y. Oka, S. Nishida, A. Tsuboi, T. Shirakata, S. Morita, J. Sakamoto, H. Sugiyama, T. Kimura

    5081 Background: Wilms' tumor gene WT1, which has an oncogenic function, is expressed in various kinds of hematological malignancies and solid cancers. The WT1 protein is highly immunogenic and is considered to be a promising target of cancer treatment. On the clinical trials of WT1 peptide vaccine, the decrease of leukemic cells, shrinkage of solid tumor and long-term dormancy of malignancies are reported. We intend to report the clinical trials of WT1 peptide vaccine to gynecologic malignancies which are resistant to conventional therapies. Methods: Twenty one cases of gynecologic malignancy (12 cases of ovarian cancer, 4 of cervical cancer, 1 of endometrial cancer and 4 cases of other malignant tumor), which are resistant to first-/second-line therapy, were included to the trial. After obtainment of informed consent, modified WT1235 type peptide is injected intracutaneously to the HLA-A*2402- positive patients, whose tumor tissues expressed WT1 protein. The injection was repeated weekly to total of 12 times. Immune response to WT1 peptide was monitored with delayed type hypersensitivity (DTH). Side effect due tothe injection was also monitored. The antitumor effect was assessed based on Response Evaluation Criteria in Solid Tumors (RECIST). If any clinical effect is observed, the injection of the vaccine was continued biweekly. Results: In 15 (71%) of 21 patients, the 12 times of injection are completed. In remaining 6 cases, injection had been stopped due to worsening of performance status. Only 1 patient showed grade 3 vesicle at the injection site, however, no patient was cancelled the injection due to severe side effect. The SD status in RECIST criteria is observed in 5 (24%) patients and the injection is continued for these 5 patients, with the maximum of 29 times. Patients who is positive to DTH reaction during therapy, showed significantly longer overall survival than patients who are negative to DTH through the treatment. Conclusions: It was considered that the induction of WT1-specific immunological responses contributed to the occurrence of clinical responses. Some patients reached long-term dormancy of the tumor. We recognized the WT1 peptide vaccine is a new strategy for gynecologic malignancies. No significant financial relationships to disclose.

  • Endometrial carcinoma: better prognosis for asymptomatic recurrences than for symptomatic cases found by routine follow-up

    by Yutaka Ueda, Takayuki Enomoto, Tomomi Egawa-Takata, Takashi Miyatake, Kiyoshi Yoshino, Masami Fujita, Shinya Matsuzaki, Takuhei Yokoyama, Yukari Miyoshi, Tadashi Kimura

    The aim of this study was to determine if there is a prognostic value for the presence of symptoms at the time of recurrence detection in surgically resected endometrial carcinoma patients. During the study period of 2000–2006, complete surgical removal of endometrial carcinoma was achieved in 271 stage I–IV endometrial cancer cases at the Department of Obstetrics and Gynecology of Osaka University Hospital, Osaka, Japan. A subsequent recurrence was detected in 29 (11%) of these cases. Patient characteristics and clinicopathological features were retrospectively reviewed utilizing their clinical records. Among the 29 cases with a recurrence, 13 (45%) had symptoms, whereas in the other 16 cases (55%) the recurrent disease was found only during routine follow-up procedures. Although the time to detection of recurrence was similar for both asymptomatic and symptomatic cases, progression-free survival after detection in the 16 asymptomatic patients was significantly longer than for the 13 symptomatic patients (P = 0.017); this was found to be especially true in those who underwent chemotherapy as their adjuvant therapy (P = 0.023). A better prognosis after recurrence was demonstrated in cases that were asymptomatic at the time of recurrence detection than in those in which the tumor was symptomatic. This finding implies that, after the initial surgical resection, intensive follow-up intervention looking for asymptomatic recurrences may significantly improve the prognosis of endometrial carcinoma patients. A further in-depth prospective study is required to establish a standard strategy of follow-up care for endometrial cancer patients.


  • Endometrial Carcinoma with Extra-abdominal Metastasis: Improved Prognosis Following Cytoreductive Surgery

    by Yutaka Ueda, Takayuki Enomoto, Takashi Miyatake, Tomomi Egawa-Takata, Hiromi Ugaki, Kiyoshi Yoshino, Masami Fujita, Tadashi Kimura

    Incidence of endometrial carcinoma, the most common malignancy of the female pelvis, has been steadily increasing during the last three decades. The prognosis for stage IVb cases with extra-abdominal metastases is extremely poor, with no current consensus regarding treatment. The aim of the present study was to examine the benefits of cytoreductive surgery for such cases. Clinicopathological features of 33 stage IVb cases of endometrial carcinoma diagnosed during the 1991–2008 study period were retrospectively reviewed utilizing clinical records. Cytoreduction was conducted in 30 cases. The median progression-free survival (PFS) and overall survival (OS) of those patients with optimal cytoreduction of their disease (with residual masses ≤ 2 cm), were significantly better than those with suboptimal reduction (with residual masses > 2 cm), not only among the 15 stage IVb patients with only intra-abdominal metastasis (group I) (P = 0.0003 and 0.0007) but also among the 15 cases with extra-abdominal metastasis (group E) (P = 0.013 and 0.016). Multivariate Cox proportional-hazards analysis demonstrated that the adjusted hazard ratio (HR) for the maximum size of residual disease (>2 vs. ≤2 cm) was 10.4 [95% confidence interval (CI), 1.27–84.70, P = 0.030] in group I and 16.92 (95% CI, 1.41–203.09, P = 0.026) in group E. This is the first demonstration that aggressive cytoreductive surgery for stage IVb endometrial carcinoma with extra-abdominal metastasis has a beneficial role. However, further investigation is still required to establish better standard therapy for stage IVb endometrial cancer.